Terms and Agreement
Please agree to the terms to continue using the chat feature.
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
Calidi Biotherapeutics presents a compelling opportunity as a clinical-stage biotech at the forefront of oncolytic virotherapy (OV), a promising multi-billion-dollar area in cancer treatment. Calidi is pioneering the development of both systemic and localized OVs, leveraging engineered viruses to target and destroy cancer cells while arming the immune system for a comprehensive attack on tumors. Calidi's cell-based technologies uniquely protect OVs from immune system elimination, ensuring higher efficacy and opening the tumor microenvironment to treatment. This approach has shown promising efficacy in initial studies, while their breakthrough IV-based technology and direct tumor administration methods differentiate them within the oncology field.
Targeting metastatic melanoma, glioblastoma, triple-negative breast cancer, head & neck cancer, and lung cancer, Calidi addresses a substantial and growing market with an estimated $13 billion to $15 billion annual total addressable market in the US alone. The need for effective treatments in these areas remains high, providing a significant opportunity for growth and impact. Calidi’s current development pipeline includes:
Calidi Biotherapeutics offers a unique value proposition through its innovative technology, robust development pipeline, clear market need, competitive edge, and near-term milestone catalysts, making it a compelling investment opportunity in the rapidly evolving field of cancer treatment. Three analysts cover Calidi with buy ratings and average price target of $13.30 per share (split adjusted).
Multiple partnership opportunities to potentiate and deliver other existing oncolytic virotherapies, combination therapies, and joint development of next generation therapies.
Red Chat is here to summarize the SEC filing data on CLDI
Please agree to the terms to continue using the chat feature.